Skip to content

Clinical trials

Genetic Diseases, Inborn trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Genetic Diseases, Inborn Country / region: China Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20111
20151
20161
20173
20183
20191
20213
20222
20231
20244
20253

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Recruiting11
Unknown status6
Completed5
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Hospital of Fudan University3
Genzyme, a Sanofi Company2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2
Women's Hospital School Of Medicine Zhejiang University2
Children's Hospital of Chongqing Medical University1
Eye & ENT Hospital of Fudan University1
General Hospital of Chinese Armed Police Forces1
Guangzhou Institute of Respiratory Disease1
Kyntra Bio1
PTC Therapeutics1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Genetic Diseases, Inborn23
Genetic Diseases, X-Linked4
Congenital Abnormalities3
Hematologic Diseases3
Blood Coagulation Disorders2
Blood Coagulation Disorders, Inherited2
Coagulation Protein Disorders2
Hemoglobinopathies2
Hemophilia A2
Hemophilia B2

Trials

Showing 26 to 23 of 23. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.